Obrigado, Dr. de Fronzo!
Palavras-chave:
De Fronzo, controlo glicémico, insulina na diabetes tipo 2Resumo
Os autores revêem a relação entre o controlo glicémico e as
complicações da Diabetes: relação estabelecida e demonstrada
no caso das complicações microangiopáticas mas controversa
e contraditória no caso da macroangiopatia, questionando os
objectivos do controlo “cego”das glicemias independentemente do doente concreto.
Revêem o conceito do “octeto” de De Fronzo, que advoga o
recurso prioritário a fármacos que aumentem a sensibilidade à
insulina e que preservem a função da célula β, pondo em causa
a utilização indiscriminada de vários hipoglicemiantes (incluindo
a insulina) devido ao seu papel potencialmente aterogénico. A
insulina poderia mesmo ser considerada a wrong drug na prevenção das doenças cardiovasculares.
Downloads
Referências
De Fronzo, R A – From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 Diabetes Mellitus – Diabetes (2009) 58: 773-795.
G. Sherntharner A.H. Barnrnett et al. -- Is the ADA/EASD Algorithm for the treatment of type 2 diabetes based on evidence or opinion? – Diabetologia (2010) – For Debate-53: 1258-1269, 73-75.
Diabetes Control and Complications Trial Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986.
Stratton L M. Addler A J et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. B M J 321: 405-412.
Morrich N J, Wang SL et al. (2001). Mortality and causes of death in the WHO multinational study of vascular diseases in diabetes. Diabetologia 44 (Suppl 2): S14: S21.
Holman RR, Paul SK et al. 10 years follow-up of intensive glucose con control in type 2 diabetes. N Engl J Med (2008). 359:1577-1599.
Currie CJ, Peters JR et al. – Survival as a function of Hb A1c in people with type 2 diabetes: a retrospective cohort study. Lancet (2010) 375: 481-489.
Duchtworth et al. VADT investigators. Glucose control and vascular complications in veterans with type2 diabetes. N Engl J Med (2009) 360: 129-139.
De Fronzo. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis, the missing links. The Claude Bernard Lecture 2009. Diabetologia (2010); 53: 1270-1287.
Stefano Del Prato, Giuseppe Pens et al. Changing the treatment paradigm for type 2 Diabetes. Diabetes Care (2009) 32: S217:S222.
ADVANCE Collaboration Group. Intensive blood glucose control and vascular outcomes in diabetes type 2 patients. N Engl J Med (2008) 358: 2560-2572.
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care January 2009 32:187-192.
The Action to Control Cardiovascular Risk in Diabetes Study Group (2008). Effects of intensive glucose lowering in type 2 diabetes. N Engl
J Med 358: 2545-2559.
Gernstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 Diabetes. N Engl J Med (2008).358: 2345-2359.
Victor M.Monfort et al. Glycemic control in type 2 D.M. Time for an Evidence-Based About-Face? Annals of Internal Medicine 2009; 150: 803-808.
Eurich D.T, MacAllister et al. Bennefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007)-335-497.
Del Prato S, Leonetti F, Simonson DC et al (1994). Effect of sustained physiologic hyperinsulinemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 37:1025–1035.
Kashyap SR, DeFronzo RA (2007) The insulin resistance syndrome: physiologic considerations. Diab. Vasc Dis. Res 4:13–19.
Tobey TA, Greenfield M et al. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics and plasma triglyceride levels in normotriglyceridemic man. Metabolism (1981) 30:165–171.
Wajchenberg BL. Beta cell failure in diabetes and preservation by clinical treatment Endocr Rev (2007) 28: 187:218.
Chunli Yu, Yan Chen. Mechanism by wich fatty acids inhibit activation of IRS-1 associated PI-3 kinase activity in muscle. The Journal of Biological Chemistry – 2002; De.27.
Hakan Alkhateeb et al. Two phases of palmitate-induced insulin resistance in skeletal muscle – impaired glucose GLUT-4 translocation is followed by reduced GLUT4 intrinsic activity. Am J Phisiol Endocrinol Metab (2007. 2-3; E783-3.
Kashiap S, Belfort R et al. A sustained increase in plasma free fat acid impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes (2003) 52: 2461-2474.
Kahn SE, HffnerDM et al. Glicemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med (2006) 355: 2427-2443.
Johnson JA, Majundar SR et. al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care (2002) 25: 2244-2248.
Hanefeld M et al. Glicemia control and treatement failure with pioglitazone versus glibenclamide in type2 diabetes – a 42 month, open-label observational primary care study. Cur Med Res Opinion (2006) 22:1211-1215.
Tan MH et al. Comparision of pioglitazone and gliclazide in sustaining glycemic control over two years in patients with type 2 diabetes. Diabetes Care (2005) 28: 544-550.
Bajaz et al. Effects of Pioglitazone on intramyocelular fat metabolism in patients type2 Diabetes. J Clin Endocrinol Metabol (2010); 95:1916.
Hausenloy DJ, Yellon. DM GLP-1 therapy: beyond glucose control. Cic. Heart Failure (2008) 1: 147-149.
Madsbad S. Exanatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin Mimetics) – preclinical and clinical results. Best Pract Res Clin Endocrinol Metab (2009) 23: 463-477.
Engel–Nietz NM, Martin S et al. Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clinic Pract (2008); 81:97:104.
Muis MJ, Bots ML et al. Insulin treatment and cardiovascular disease: friend or foe? A point of view. Diabetes Med. (2005)22:118-126.
De Fronzo RA. Is insulin resistance atherogenic? Possible mechanisms. Atherosclerosis (2006). 7:11-15.
Cruz AB, Amatuzio DS et al. Effect of intra arterial insulin on tissue cholesterol and fatty acids in alloxan diabetic dogs. Circ. Ris. (1961) 9:39-43.
Henry RR, Gumbiner B et al. Intensive conventional insulin therapy for type 2 diabetes. Metabolic effects during 6-month outpatient trial. Diabetes Care (1993); 16:21-31.
Holman RR, Thomo KI et al. Addition of biphasic, prandeal or basal insulin to oral therapy in type 2 diabetes. N Engl J Med (2007) 357:1716:1730.
Giorda CB, Avogaro A et al. Reccurrence of cardiovascular events in patients with type 2 diabetes; Diabetes Care 31; 2154-2159. 35.
JJ Nolan. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia. Commentary (2010) 53:1247-1249
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
